What about the mortality benefit of 9 vs 1 (Pt with metastatic liver cancer who died of bacterial infx). Plus the ability to work against multiple variants in the setting of omicron. New variants make monoclonal antibodies less effective as evidenced by regeneron CEO comments.
-
-
-
The data also suggested Molnupiravir was less effective against Delta. How effective do you think it will be against Omicron? They never satisfactorily answered how the second half LPD of the trial was so ineffective…Delta seems the only real answer.
End of conversation
New conversation -
-
-
Look at Gilead and MTNB oral Resdemsiver using MTNB LNC platform to deliver it safely. Have you thought or know about it??
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thanks for participating in this!
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Good man. You made the right call.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Thank you for your work on this. Clearly a difficult decision.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Courageous vote. Well done. The question to the panel should have been “based on the data presented today, if you had symptoms of Covid-19 would you take these pills to prevent disease progression and possibly death?”
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
I am in your camp, the reduction is not significant and the associated risk is an intrinsic threat to all.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Profit motive must no longer be a part of health care in the USA. Only highly effective remedies with low side effects should be allowed in production.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.